Struggling rare diseases company Novelion Therapeutics (Nasdaq: NVLN) admitted further difficulties on Tuesday related to its Aegerion subsidiaries.
The Canadian company announced that it would be unable to file its Quarterly Report on Form 10-Q for the second quarter on time, including the related management’s discussion and analysis and chief executive and chief financial officer certifications.
A form 12b-25, a notification of late filing, has therefore been sent to the US Securities and Exchange Commission (SEC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze